Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2003
07/15/2003US6592845 Administering 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline to a patient suffering from or at risk of developing ALS in order to reduce symptoms or delay onset of ALS.
07/15/2003CA2316731C Concentrated and stabilized antipyretic compound for veterinary use to be added to animal feed and process for adding the said compound to animal drinking water
07/15/2003CA2286013C Process for making a butylthio-isoquinoline and intermediates therefor
07/15/2003CA2262269C Treatment of skeletal disorders
07/15/2003CA2245938C Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
07/15/2003CA2238465C Triaromatic compounds, compositions containing them and uses
07/15/2003CA2218766C Bicyclic-aromatic compounds
07/15/2003CA2208047C Increasing creatine and glycogen concentration in muscle
07/15/2003CA2180843C Pyridine modulators of acetylcholine receptors
07/15/2003CA2139864C Use of a calcium carbonate based porous material as support for a growth factor in the preparation of a bioabsorbable implant
07/15/2003CA2095889C Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients
07/15/2003CA2086221C Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agent
07/15/2003CA2077562C Diastereomers of 1-(isopropoxycarbonyloxy) ethyl 3-cephem-4-carboxylate and processes for their preparation
07/15/2003CA2067408C 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors
07/15/2003CA2059817C Polyamine thiols as radioprotective agents
07/14/2003WO2003059878A2 Thieno (3, 2-b) pyridones as antiviral compounds
07/14/2003CA2472960A1 Thieno (3, 2-b) pyridones as antiviral compounds
07/10/2003WO2003056013A1 TGF-β-SPECIFIC COVALENTLY CLOSED ANTISENSE MOLECULE
07/10/2003WO2003056012A1 A system for stable expression of sirnas in mammalian cells
07/10/2003WO2003055991A1 Igamete recruitment and developmental competence in mammals by inhibiting the de novo sterol biosynthesis and/or promoting sterol efflux
07/10/2003WO2003055984A1 New strain of lactic acid bacterium and edible compositions, drugs and veterinary products containing it
07/10/2003WO2003055983A2 Targeted retrograde gene delivery to motor neurons
07/10/2003WO2003055980A2 Il-17 like molecules and uses thereof
07/10/2003WO2003055977A2 A method for generating overexpression of alleles in genes of unknown function
07/10/2003WO2003055918A1 Negatively charged polysaccharide derivable from aloe vera
07/10/2003WO2003055915A2 Human netrin receptor and uses thereof
07/10/2003WO2003055913A2 Secreted protein
07/10/2003WO2003055912A2 Secreted proteins
07/10/2003WO2003055910A1 Beta-amyloid binding factors and inhibitors thereof
07/10/2003WO2003055897A1 Method for preparing a glucosamine compound, and compound thus obtained
07/10/2003WO2003055896A2 Anti-viral 7-deaza l-nucleosides
07/10/2003WO2003055891A1 Streptogramin derivatives, preparation thereof and compositions containing same
07/10/2003WO2003055884A1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
07/10/2003WO2003055883A1 Pyrimidotriazines as phosphatase inhibitors
07/10/2003WO2003055882A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors
07/10/2003WO2003055881A1 Pyrido(2,1-a)isoquinoline derivatives as dpp-iv inhibitors
07/10/2003WO2003055880A2 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same
07/10/2003WO2003055877A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
07/10/2003WO2003055876A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
07/10/2003WO2003055875A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055874A1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055873A1 Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
07/10/2003WO2003055871A1 DECAHYDRONAPHTHO[2,3-c]FURAN DERIVATIVES
07/10/2003WO2003055868A1 Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors
07/10/2003WO2003055867A1 Biphenylmethyl-thiazolidinediones and analogues and their use as ppar-gamma activators
07/10/2003WO2003055865A1 Quinazolinone derivative
07/10/2003WO2003055864A1 Long chain fatty alcohol substituents in antineoplastic agents
07/10/2003WO2003055863A1 Novel alkansulfonamides as endothelin antagonists
07/10/2003WO2003055861A1 Benzocyclodecane derivatives with antitumor activity
07/10/2003WO2003055860A1 3,4-diarylpyrazoles and their use in the therapy of cancer
07/10/2003WO2003055855A1 Method of obtaining novel lutein-based formulations
07/10/2003WO2003055854A1 2-substituted vitamin d derivatives
07/10/2003WO2003055848A2 Urea derivatives as vr1- antagonists
07/10/2003WO2003055847A1 Carboxylic acid derivative
07/10/2003WO2003055559A1 Dialkyl-substituted acetic acid and glyceric acid based active substance combinations against bacteria, mycota and viruses
07/10/2003WO2003055549A1 Metered dose inhaler
07/10/2003WO2003055547A1 Medicament dispenser
07/10/2003WO2003055532A1 Disinfection agent for suction systems used in the field of medicine
07/10/2003WO2003055529A1 Dna vaccine for periodontal disease
07/10/2003WO2003055525A1 Acid-containing preparations
07/10/2003WO2003055523A1 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes
07/10/2003WO2003055522A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
07/10/2003WO2003055521A1 Remedies for mild recognition deflict
07/10/2003WO2003055516A1 Pecam-1 modulation
07/10/2003WO2003055510A1 Therapy for growth hormone induced insulin resistance in juveniles with growth disorders
07/10/2003WO2003055508A1 Composition for the treatment of renal failure or gastric dysfunction of e.g. premature or neonatal mammals
07/10/2003WO2003055506A1 Preventives/remedies for cancer
07/10/2003WO2003055504A1 Pharmaceutical composition for prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation
07/10/2003WO2003055500A1 Pharmaceutical compositions for the treatment or prevention of osteoporosis
07/10/2003WO2003055499A1 Use of sulfated glycosaminoglycans for establishing effective labor in women
07/10/2003WO2003055498A1 Composition comprising dextrinsulfate for the treatment of sexual transmitted diseases (std)
07/10/2003WO2003055497A1 Buffalo milk gangliosides
07/10/2003WO2003055496A1 Method for the treatment of bone disorders
07/10/2003WO2003055495A1 ORAL PHARMACEUTICAL PRODUCTS CONTAINING 17β-ESTRADIOL-3-LOWER ALKANOATE, METHOD OF ADMINISTERING THE SAME AND PROCESS OF PREPARATION
07/10/2003WO2003055494A1 Use of ugt inhibitors to increase bioavailability
07/10/2003WO2003055493A1 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation
07/10/2003WO2003055492A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
07/10/2003WO2003055491A1 Substituted quinazoline derivatives as inhibitors of aurora kinases
07/10/2003WO2003055488A1 Remedies or preventives for diseases in association with tissue fibrosis
07/10/2003WO2003055487A1 METHOD OF CONTROLLING DAMAGE MEDIATED BY α, β- UNSATURATED ALDEHYDES
07/10/2003WO2003055486A1 A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity
07/10/2003WO2003055485A1 Dosing regimen for ppar-gamma activators
07/10/2003WO2003055484A1 Urea derivatives
07/10/2003WO2003055483A1 Famotidine injection
07/10/2003WO2003055482A1 Amide derivatives as gk activators
07/10/2003WO2003055481A1 Organ fibrosis inhibitors
07/10/2003WO2003055480A1 Products for use in immunosuppressive therapy containing lipoic acid and a calcineurin inhibitor
07/10/2003WO2003055478A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
07/10/2003WO2003055477A1 Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
07/10/2003WO2003055475A1 Controlled release pharmaceutical formulation containing venlafaxine
07/10/2003WO2003055474A1 Treatment of faecal incontinence and other conditions with 1r, 2s-methoxamine
07/10/2003WO2003055473A1 Regulation of nad(p)h oxidase growth and transcription in melanoma cells
07/10/2003WO2003055472A1 Gel comprising at least a retinoid and benzoyl peroxide
07/10/2003WO2003055469A1 Improved polymer-lipid delivery vehicles
07/10/2003WO2003055467A1 Simvastatin dosage forms
07/10/2003WO2003055465A1 Preparation for the topical anaesthesia of the skin
07/10/2003WO2003055464A1 Micronized pharmaceutical or nutraceutical powder with immediate release
07/10/2003WO2003055463A1 Composition comprising at least an oxazolin for inhibiting langerhans cell migration, and uses thereof
07/10/2003WO2003055462A2 Composition comprising at least an alkanolamide for inhibiting langerhans cell migration, and uses thereof
07/10/2003WO2003055456A1 Stable surfactant compositions for suspending components
1 ... 5409 5410 5411 5412 5413 5414 5415 5416 5417 5418 5419 5420 5421 5422 5423 5424 5425 5426 5427 5428 5429 ... 7860